Mesenchymal stem cells therapy exerts neuroprotection in mice model of Parkinson's disease

BACKGROUND: Parkinson’s disease (PD) is the second most common neurodegenerative disorder after Alzheimer’s disease and is expected to impose an increasing social and economic burden on societies as populations age. The ground-breaking developments in stem cell research in the last decade have revived the interest for intracerebral cell transplantation as a therapeutically approach for PD. The experimental research with intranasal administration of stem cells in PD mouse model can work and in some cases induce major, long-lasting improvement. This research was done for evaluating effect of intranasal delivery of HEDSCs in mouse model of PD.METHODS: In this research, the intranasal route was used for administration of human endometrium-derived stem cells (HEDSCs)-GFP labeled in a mouse model of PD in optimal dose (5×104 cells μl-1). During 4 months after cell application, behavioral tests including rotational behavior test, rotarod test, and open field test were examined. In addition, immunohistochemistry was used to assay, GFP, human neural Nestin, and tyrosine hydroxylase (TH) markers in the fixed brain tissue at the substantia nigra pars compacta (SNpc) area.RESULTS: The result demonstrated that administration of HEDSCs can enhanced behavioral parameters compared with control group significantly. The data from immunohistochemistry analysis revealed that the GFP and also Nestin as a differential neuronal biomarker was expressed in SNpc area. Also, TH as a dopaminergic neuron marker significantly increased after cellular therapy in an optimized dose 5×104 cells μl-1.CONCLUSIONS: Our investigation revealed that cellular therapy with HEDSCs improved the PD symptoms in the mouse model of PD as an effective method.

کلیدواژه ها:

Parkinson’s disease ، Mesenchymal stem cells ، Cell therapy ، Dopaminergic neurons ، Neurogenesis